AstraZeneca Updates 2030 Sustainability Goals as AI and Emissions Cuts Take Center Stage

AstraZeneca Updates 2030 Sustainability Goals as AI and Emissions Cuts Take Center Stage

AstraZeneca updated its 2030 sustainability targets, lowering its Scope 3 emissions goal to a 35% reduction from 2019 and revising its AZ Forest target to 100 million trees. The company said the changes reflect business growth, lessons learned, and a focus on higher-quality projects.

The company highlighted major decarbonization progress, including an 88% cut in Scope 1 and 2 emissions, a transition to electric vehicles, and a $500 million push to replace inhaler propellants with a near-zero warming alternative. AstraZeneca said the inhaler transition is a critical lever because pMDIs account for 26% of its Scope 3 footprint.

AI is becoming a core tool across AstraZeneca’s R&D, manufacturing, and diagnosis efforts, with the company targeting about 35% productivity improvement and 50% faster lead times by 2030. It is also using AI in early disease detection and maintaining strict governance rules for approved use only.

Astrazeneca NYSE: AZN told investors and analysts that it is continuing to embed sustainability into its business strategy while updating some of its 2030 targets to reflect growth and lessons learned from existing programs. During the company’s 2026 Sustainability Update, Pam Cheng, EVP Global Operations and Chief Sustainability Officer, said AstraZeneca views health, society and the environment as interconnected. She said climate change, nature loss, aging populations, chronic disease and health disparities are increasing pressure on healthcare systems, while early disease detection and more sustainable care can improve outcomes and reduce system burdens.